ISSN:
1432-1041
Keywords:
diabetes mellitus
;
Bay m 1099
;
Type II diabetic patients
;
desoxynojirimycin
;
alpha-glucosidase inhibitor
;
metabolic effects
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Bay m 1099 is a newly developed inhibitor of intestinalα-glucosidase. Its ability to lower postprandial plasma glucose, serum insulin and C-peptide levels in Type II diabetics has been investigated. Fifteen obese Type II diabetic patients with inadequate metabolic control during sulphonylurea treatment received a standardized diet and were treated either with Bay m 1099, b.d. (100 mg before breakfast and dinner) or placebo for 3 days, according to a double-blind cross-over design. The postprandial blood glucose level was significantly lower during Bay m 1099 treatment compared to placebo after breakfast and dinner (AUC after breakfastp〈0.001). The reduced postprandial hyperglycaemia was associated with a decrease in meal stimulated serum insulin and C-peptide levels. Thus, Bay m 1099 may be a useful addition in the treatment of Type II diabetic patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00607953
Permalink
